Literature DB >> 24147780

N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein.

Barney Yoo1, Sarah M Cheal, Geralda Torchon, Anna Dilhas, Guangbin Yang, Jun Pu, Blesida Punzalan, Steven M Larson, Ouathek Ouerfelli.   

Abstract

Dendrimer clearing agents represent a unique class of compounds for use in multistep targeting (MST) in radioimmunotherapy and imaging. These compounds were developed to facilitate the removal of excess tumor-targeting monoclonal antibody (mAb) prior to administration of the radionuclide to minimize exposure of normal tissue to radiation. Clearing agents are designed to capture the circulating mAb, and target it to the liver for metabolism. Glycodendrons are ideally suited for MST applications as these highly branched compounds are chemically well-defined, thus advantageous over heterogeneous macromolecules. Previous studies have described glycodendron 3 as a clearing agent for use in three-step MST protocols, and early in vivo assessment of 3 showed promise. However, synthetic challenges have hampered its availability for further development. In this report we describe a new sequence of chemical steps which enables the straightforward synthesis and analytical characterization of this class of dendrons. With accessibility and analytical identification solved, we sought to evaluate both lower and higher generation dendrons for hepatocyte targeting as well as clearance of a model protein. We prepared a series of clearing agents where a single biotin is connected to glycodendrons displaying four, eight, sixteen or thirty-two α-thio-N-acetylgalactosamine (α-SGalNAc) units, resulting in compounds with molecular weights ranging from 2 to 17 kDa, respectively. These compounds were fully characterized by LCMS and NMR. We then evaluated the capacity of these agents to clear a model (131)I-labeled single chain variable fragment antibody-streptavidin ((131)I-scFv-SAv) fusion protein from blood and tissue in mice, and compared their clearing efficiencies to that of a 500 kDa dextran-biotin conjugate. Glycodendrons and dextran-biotin exhibited enhanced blood clearance of the scFv-SAv construct. Biodistribution analysis showed liver targeting/uptake of the scFv-SAv construct to be 2-fold higher for compounds 1 to 4, as well as for the 500 kDa dextran, over saline. Additionally, the data suggest the glycodendrons clear through the liver, whereas the dextran through reticuloendothelial system (RES) metabolism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24147780      PMCID: PMC3900322          DOI: 10.1021/bc400333m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  32 in total

1.  Nonswelling macroporous synbeads for improved efficiency of solid-phase biotransformations.

Authors:  Alessandra Basso; Paolo Braiuca; Luigi De Martin; Cynthia Ebert; Lucia Gardossi; Paolo Linda; Silvia Verdelli; Andrea Tam
Journal:  Chemistry       Date:  2004-02-20       Impact factor: 5.236

2.  In vivo chemistry for pretargeted tumor imaging in live mice.

Authors:  Raffaella Rossin; Pascal Renart Verkerk; Sandra M van den Bosch; Roland C M Vulders; Iris Verel; Johan Lub; Marc S Robillard
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-26       Impact factor: 15.336

Review 3.  Dendrimers for vaccine and immunostimulatory uses. A review.

Authors:  Peter M H Heegaard; Ulrik Boas; Nanna Skall Sorensen
Journal:  Bioconjug Chem       Date:  2009-11-04       Impact factor: 4.774

4.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

5.  Human hepatic lectin. Physiochemical properties and specificity.

Authors:  J U Baenziger; Y Maynard
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

6.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.

Authors:  O W Press; M Corcoran; K Subbiah; D K Hamlin; D S Wilbur; T Johnson; L Theodore; E Yau; R Mallett; D L Meyer; D Axworthy
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

8.  Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.

Authors:  Scott S Graves; Erica Dearstyne; Yukang Lin; Yuting Zuo; James Sanderson; Jody Schultz; Anastasia Pantalias; David Gray; Don Axworthy; H Mark Jones; Karen Auditore-Hargreaves
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

9.  Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

Authors:  Nai-Kong V Cheung; Shakeel Modak; Yukang Lin; Hongfen Guo; Pat Zanzonico; John Chung; Yuting Zuo; James Sanderson; Sibylle Wilbert; Louis J Theodore; Donald B Axworthy; Steven M Larson
Journal:  J Nucl Med       Date:  2004-05       Impact factor: 10.057

10.  Pretargeted molecular imaging and radioimmunotherapy.

Authors:  David M Goldenberg; Chien-Hsing Chang; Edmund A Rossi; William J; Robert M Sharkey
Journal:  Theranostics       Date:  2012-05-17       Impact factor: 11.556

View more
  2 in total

1.  Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.

Authors:  Sarah M Cheal; Barney Yoo; Sarah Boughdad; Blesida Punzalan; Guangbin Yang; Anna Dilhas; Geralda Torchon; Jun Pu; Don B Axworthy; Pat Zanzonico; Ouathek Ouerfelli; Steven M Larson
Journal:  Mol Pharm       Date:  2013-11-23       Impact factor: 4.939

2.  An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.

Authors:  Sarah M Cheal; Mitesh Patel; Guangbin Yang; Darren Veach; Hong Xu; Hong-Fen Guo; Pat B Zanzonico; Donald B Axworthy; Nai-Kong V Cheung; Ouathek Ouerfelli; Steven M Larson
Journal:  Bioconjug Chem       Date:  2020-02-10       Impact factor: 4.774

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.